VIRGINIA RETIREMENT SYSTEMS ET Al Has $14.47 Million Stock Holdings in Amgen Inc. $AMGN

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 31.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 44,200 shares of the medical research company’s stock after buying an additional 10,609 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Amgen were worth $14,467,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of AMGN. Robeco Institutional Asset Management B.V. increased its stake in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after buying an additional 43,884 shares during the last quarter. Sequoia Financial Advisors LLC increased its stake in Amgen by 2.3% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after buying an additional 3,619 shares during the last quarter. Curtis Advisory Group LLC acquired a new stake in Amgen in the 4th quarter valued at $1,669,000. Global Wealth Management Investment Advisory Inc. increased its stake in Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after buying an additional 4,699 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its stake in Amgen by 18.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after buying an additional 6,115 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. UBS Group lifted their price target on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Canaccord Genuity Group assumed coverage on shares of Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 price target on the stock. Argus lifted their price target on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Barclays started coverage on shares of Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective on the stock. Finally, Morgan Stanley set a $332.00 price objective on shares of Amgen in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $356.35.

Amgen Stock Up 0.0%

Amgen stock opened at $336.45 on Thursday. The firm has a market capitalization of $181.58 billion, a PE ratio of 23.41, a P/E/G ratio of 3.38 and a beta of 0.44. The company’s 50-day moving average is $351.05 and its 200-day moving average is $342.80. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.36 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen’s dividend payout ratio is 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.